Anti-TNF antibodies, compositions, methods and uses
OwnerJill Giles-Komar, Bernard J. Scalloninventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Claims25
At least one isolated mammalian ANTI-TNF antibody, comprising at least one variable region comprising at least one heavy chain and at least one 5 light chain of SEQ ID NOS:7-8.
At least one isolated mammalian ANTI-TNF antibody, comprising either (i) at least two of the heavy chain complementarity determining regions (CDR) amino acid sequences of at least one of SEQ ID NOS:1-3;
- or (ii) at least two of the light chain CDR amino acids sequences of at least one of SEQ ID NOS:4-6.
At least one isolated mammalian ANTI-TNF antibody, comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:7-8
At least one isolated mammalian ANTI-TNF antibody that binds to the same region of a ANTI-TNF polypeptide as an antibody comprising at least one heavy chain or light chain CDR having the amino acid sequence of at least one of SEQ ID NOS:1, 2, 3, 4, 5, or 6.
At least one isolated mammalian ANTI-TNF antibody, comprising at least one human CDR, wherein said antibody specifically binds at least one epitope comprising at least 1-3, to the entire amino acid sequence of SEQ ID NO:9.
An ANTI-TNF antibody according to any of claims 1-6, wherein said antibody binds ANTI-TNF with an affinity of at least one selected from at least 10−9 M, at least 1010 M, at least 10−11 M, or at least 10−12 M.
An isolated nucleic acid vector comprising an isolated nucleic acid according to claim 9.
A method according to 16, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or polypeptide selected from at least one of a detectable label or reporter, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplactic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, or a cytokine antagonist.
Any invention described herein.
Dependencies are inferred from the claim text.